AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comSEP 222 min read$RARE

FDA Approves Fayuvi. What Does It Mean for Ultragenyx (RARE)’s 2027 Profitability Target?

Ultragenyx (RARE) received FDA approval for Fayuvi, a treatment for Sanfilippo syndrome Type A, causing a 12% stock jump. The company aims for profitability by 2027, with Fayuvi expected to contribute significantly to revenue. Fayuvi is priced at $3.95 million per treatment, with estimated peak sales of $200M-$250M. Hedge funds and short interest activity increased before the approval.

Original reporting
finance.yahoo.com
Published Sep 22, 2026, 10:18 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 22, 2026, 11:05 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
FDA Approves Fayuvi. What Does It Mean for Ultragenyx (RARE)’s 2027 Profitability Target? — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$RAREBullishHigh
01

Why it matters

The approval is a material regulatory event that could materially improve revenue and earnings outlook, justifying the stock's recent rally.

02

Market read

First FDA approval for a fatal childhood disorder; introduces a multi‑hundred‑million‑dollar revenue stream and supports long‑term profitability goals.

03

What to watch

Potential delays in payer coverage decisions and limited patient identification could curb sales.

Relevance 9/10Novelty 9/10Timing: after FDA approval (Sept 17) – immediate market reaction

Background

Ultragenyx (RARE) reported a $575M loss in 2025 and is targeting profitability by 2027; Fayuvi adds a high‑priced orphan drug to its portfolio.

Company-level read

Ticker impact

$RAREBullishHigh confidence
Context

FDA approval of Fayuvi, the first treatment for Sanfilippo syndrome Type A, caused a >12% stock jump and adds a high‑priced product to Ultragenyx's pipeline.

Expected impact

upward pressure on RARE in the near term, potential further gains if commercial uptake exceeds expectations

Evidence & confidence

The drug's $3.95M list price and early commercial launch timeline suggest material earnings contribution; market already reacted positively.

Market effects

Sector

Strengthens the rare‑disease biotech sector as a successful FDA approval example.

Regional

Positive for US biotech investors, may boost related ADRs.

Global

Highlights growing market for ultra‑high‑price orphan drugs worldwide.

Counterpoint

What could challenge this read

The 12% rally may already price in most upside; further gains limited if reimbursement stalls.

Key entities

  • company
    Ultragenyx Pharmaceutical Inc.

    US‑listed biotech developing rare‑disease therapies (ticker RARE).

  • product
    Fayuvi

    FDA‑approved treatment for Sanfilippo syndrome Type A.

Read at source← All news

Related articles

SEP 22
$RAREHighAI 8/10

RARE Stock Climbs This Week As Investors Look Past Trial Failure To Gene Therapy Launches, Trial Results

Ultragenyx Pharmaceutical (RARE) shares rose 9% this week after FDA approved Fayuvi, a gene therapy for Sanfilipso syndrome, and raised price targets. The stock rebounded from a 44% drop after its Angelman syndrome trial failed. Analysts see value in its $1.4B market cap and new therapies. RARE plans to sell priority review vouchers for ~$400M.

stocktwits.com2 min
SEP 18
$RAREHighAI 9/10

FDA approves gene therapy for ultra

The FDA approved Ultragenyx's gene therapy Fayuvi (rebisufligene etisparvovec) for Sanfilippo syndrome type A. The drug, priced at $3.95M per dose, is the first treatment for this rare pediatric disease. Ultragenyx's stock (RARE) rose over 12% following the approval, which also included another gene therapy, Genglycos, priced at $2.7M.

bioxconomy.com2 min
SEP 18
$RAREMed

Weekly Buzz: RARE, BAYRY Win Approvals; SION Cuts Jobs, GSK Deals; AZN, RHHBY Lead

Ultragenyx (RARE) gained FDA approval for FAYUVI, a treatment for Sanfilippo syndrome Type A, closing at $14.50, up 12.58%. Nuvation Bio (NUVB) expanded IBTROZI's label with new lung cancer data, closing at $6.07, up 5.02%. Bayer (BAYRY) won FDA approval for Kerendia in type 1 diabetes-related CKD, closing at $14.13, up 0.57%. Biogen (BIIB) and Eisai (ESALY.PK) received Japan approval for LEQEMBI Pen, closing at $219.05, up 1.41%. Telix (TLX) got FDA approval for Pixclara, a PET imaging agent fo

rttnews.com3 min
SEP 18
$RAREMedAI 8/10

Cantor Fitzgerald raises Ultragenyx stock price target on gene therapy approval

Cantor Fitzgerald raised its price target for Ultragenyx (RARE) to $39 from $33 after FDA approval of its gene therapy, FAYUVI, for Sanfilippo syndrome type A. The stock trades at $14.50, below the analyst consensus range. Cantor increased its success probability estimate and pricing forecast, including a priority review voucher sale. Despite a 37% YTD decline, InvestingPro suggests the shares are undervalued.

investing.com2 min
SEP 18
$ABEOHighAI 9/10

Abeona Therapeutics Inc.: Abeona Therapeutics Congratulates Ultragenyx on U.S. FDA Approval of FAYUVI Gene Therapy for Sanfilippo Syndrome Type A (MPS IIIA)

Abeona Therapeutics (ABEO) congratulated Ultragenyx (RARE) on FDA approval of FAYUVI, a gene therapy for Sanfilippo syndrome type A (MPS IIIA). Abeona initially developed the therapy and licensed it to Ultragenyx in 2022, making it eligible for milestone payments and royalties. FAYUVI addresses a rare, progressive neurodegenerative disease with high unmet medical need.

finanznachrichten.de2 min